Trius Therapeutics, Inc.

Trius Therapeutics, Inc.

Sector: Pharmaceutical Preparations Region: CA, United States

: | Nasdaq: TSRX

Similar to: Skystar Bio-Pharmaceutical Co., Hutchison China MediTech Ltd., Pernix Therapeutics Holdings, Inc.

Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.

× We're Sorry! We do not have an investor kit available for this company. Tell us you want one!

Investor Calendar

News & Analysis

You may also be interested in: